摘要
目的研究铝镁匹林在脑梗死恢复期使用的有效性及安全性,从而为脑梗死患者提供新的诊疗思路。方法前瞻性选择我院诊疗的80例脑梗死患者,时间节点为2021年10月01日-2022年09月30日,同时采用随机数字表法将所选患者分成2组,每组40例。使用阿司匹林肠溶片治疗为对照组患者,使用铝镁匹林片治疗为研究组患者,两组均治疗至少3个月。研究分析两组患者临床疗效和安全性指标。结果治疗3个月后,研究组脑梗死复发率(2.56%)和对照组(5.13%),差异不显著(χ^(2)=1.054,P=0.305);研究组及对照组患者均有神经功能改善(NIHSS评分),且研究组神经功能改善程度(6.06±1.87)优于对照组(9.49±0.79)(t=10.552,P<0.05)。治疗6个月后,研究组脑梗死复发率(10.26%)和对照组(15.38%),差异不显著(χ^(2)=0.459,P=0.498)。服药后6个月内,研究组患者并发症发生率仅为5.13%,而对照组患者为20.51%,两组比较,差异非常明显(χ^(2)=4.129,P=0.042)。研究组患者的Baethel指数评分(85.63±9.82)明显高于对照组(71.65±10.52)(t=6.067,P<0.05)。结论铝镁匹林在脑梗死恢复期使用,在脑梗死复发率方面不劣于阿司匹林肠溶片;其神经功能改善程度优于阿司匹林肠溶片,可提高患者的日常自理能力,提高治疗有效率;但与使用阿司匹林肠溶片相比,可减低不良反应的发生率,尤其在减少消化道不良反应方面似更有优势。
Objective The effectiveness and safety of aluminum magnesium aspirin in the recovery period of cerebral infarction are studied,so as to provide new diagnosis and treatment ideas for patients with cerebral infarction.Methods We prospectively selected 80 patients with cerebral infarction in our hospital,from October 1,2021 to September 30,2022,and the selected patients were divided into two groups of 40 patients in each group.For control patients,patients in the study group,for both groups for 3 months.The study analyzed the clinical efficacy and safety indicators of both patient groups.Results After 3 months of treatment,the recurrenc rate of cerebral infarction in the study group(2.56%)and the control group(10.26%)was not significant(χ^(2)=1.054,P=0.305);the patients in the study and control groups had neurological improvement(NIHSS score),and the degree of neurological improvement in the study group(6.06±1.87)was better than the control group(9.49±0.79)(t=10.552,P<0.05).And after 6 months of treatment,the recurrence rate of cerebral infarction(10.26%)and the control group(15.38%)was not significant 0.459,(χ^(2)=P=0.498).Regarding complications,the incidence of patients in the study group was only 5.13%,but 20.51%in the control group.Comparing the two groups,the difference was very obvious(χ^(2)=4.129,P=0.042).The Baethel index score in the study group(85.63±9.82)was significantly higher than the control group(71.65±10.52)(t=6.067,P<0.05).Conclusions Aluminum magnesium aspirin in the treatment of cerebral infarction,the recurrence rate of cerebral infarction is not inferior to aspirin enteric-coated tablets;its neurological improvement degree is better than that of aspirin enteric-coated tablets,which can improve the daily self-care ability of patients and improve the efficiency of treatment,but compared with single aspirin enteric-coated tablets,can reduce the incidence of adverse reactions,especially in reducing the adverse reactions of the digestive.
作者
冯燕
宋晓玲
FENG Yan;SONG Xiaoling(Department of Neurology,Genertec Medical Chengfei Hospital,Chengdu 610091,Sichuan,China)
出处
《航空航天医学杂志》
2025年第7期769-772,共4页
Journal of Aerospace medicine
关键词
铝镁匹林
脑梗死恢复期
临床疗效
安全性
Aluminum magnesium pilin
Recovery period of cerebral infarction
Clinical efficacy
Safety
